Video Center

Category:
Filter:

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are nearing approval

Published: 04 May 2017

Recent Videos

David Quinn, MD, explains the impact of data being presented at ASCO GU20 regarding neoadjuvant bladder cancer

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, explains the impact of data being presented at ASCO ...

David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, discuses best utilization of stereotactic radiation in the management ...

David Quinn, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in advanced renal cell carcinoma patients

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, on the results of long term follow up of ...

David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, describes whether biomarkers are able to aid in guiding ...

Scott Tawaga, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive non muscle invasive bladder cancer

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares perspective on the study ...

Scott Tawaga, MD, explains intravesical therapies being developed given there is a BCG shortage

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, explains intravesical therapies being developed ...

Scott Tawaga, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares results of phase 1 ...

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

Dr. Zhang, Assistant Professor of Medicine, Duke University School of Medicine, shares results of the 5 year follow up of ...

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

Dr. McGregor, Clinical Director, Dana Farber Cancer Institute, discusses strategy when treating metastatic renal cell cancer patients whose cancer returns ...

Nicolas Salgia, BSc, on ways ethnicity impacts 1st line metastatic renal cell carcinoma patients receiving targeted therapy

Dr. Salgia, BSc, City of Hope, on the impact of ethnicity on outcomes in 1st line metastatic renal cell carcinoma ...

Related Videos

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients

David Quinn, MD, on how the measurement of CTC may or may not be changing the treatment of urothelial cancer

Michael Atkins, MD, on metastatic renal cancer patients whose cancer returns and were previously treated with I-O

Landon Brown, MD, on using CTC to sub classify patients and identifying patients with biomarkers

David Quinn, MD, explains the impact of data being presented at ASCO GU20 regarding neoadjuvant bladder cancer

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

Michael Atkins, MD, shares exciting potential of current late-stage clinical studies in renal cell cancer patients

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

Nicolas Salgia, BSc, on ways ethnicity impacts 1st line metastatic renal cell carcinoma patients receiving targeted therapy

Daniel P. Petrylak, MD, expresses the efficacy of infigratinib in FGFR3-altered metastatic urothelial cancer patients

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

Daniel P. Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in metastatic castration resistant prostate cancer

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

Daniel P. Petrylak, MD, explains the effect of second antigen spread in metastatic castration resistant prostate cancer patients

Arlene Siefker-Radtke, MD, shares the role of selecting mutations vs amplification for urothelial cancer treatment

Scott Tawaga, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer